natgillin/translations-raw huggingface dataset:
What Aprovel looks like and contents of the pack Aprovel 150 mg film-coated tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2872 engraved on the other side. 
Aprovel 150 mg filmom obložene tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2872 na drugoj strani.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 300 mg of irbesartan. 
Jedna filmom obložena tableta sadrži 300 mg irbesartana.
White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2771 engraved on the other side. 
Bijela do gotovo bijela, bikonveksna, ovalna tableta, s utisnutom oznakom srca na jednoj i brojem 2771 na drugoj strani.
Hepatobiliary disorders: Uncommon: jaundice Not known: 
Poremećaji jetre i žuči Manje često: žutica Nepoznato:
EU/1/97/046/021 - 14 tablets EU/1/97/046/022 - 28 tablets EU/1/97/046/035 - 30 tablets EU/1/97/046/023 - 56 tablets EU/1/97/046/024 - 56 x 1 tablets EU/1/97/046/032 - 84 tablets EU/1/97/046/038 - 90 tablets EU/1/97/046/025 - 98 tablets 
EU/1/97/046/021 - 14 tableta EU/1/97/046/022 - 28 tableta EU/1/97/046/035 - 30 tableta EU/1/97/046/023 - 56 tableta EU/1/97/046/024 - 56 x 1 tableta EU/1/97/046/032 - 84 tableta EU/1/97/046/038 - 90 tableta EU/1/97/046/025 - 98 tableta
EU/1/97/046/016 - 14 tablets EU/1/97/046/017 - 28 tablets EU/1/97/046/034 - 30 tablets EU/1/97/046/018 - 56 tablets EU/1/97/046/019 - 56 x 1 tablets EU/1/97/046/031 - 84 tablets EU/1/97/046/037 - 90 tablets EU/1/97/046/020 - 98 tablets 
EU/1/97/046/016 - 14 tableta EU/1/97/046/017 - 28 tableta EU/1/97/046/034 - 30 tableta EU/1/97/046/018 - 56 tableta EU/1/97/046/019 - 56 x 1 tableta EU/1/97/046/031 - 84 tableta EU/1/97/046/037 - 90 tableta EU/1/97/046/020 - 98 tableta
Blood and lymphatic system disorders Not known: 
Poremećaji krvi i limfnog sustava
Each tablet contains: irbesartan 150 mg 
Jedna tableta sadrži 150 mg irbesartana
What Aprovel looks like and contents of the pack Aprovel 300 mg tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2773 engraved on the other side. 
Aprovel 300 mg tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2773 na drugoj strani.
White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2773 engraved on the other side. 
Bijela do gotovo bijela, bikonveksna, ovalna tableta, s utisnutom oznakom srca na jednoj i brojem 2773 na drugoj strani.
EU/1/97/046/012 - 14 tablets EU/1/97/046/007 - 28 tablets EU/1/97/046/008 - 56 tablets EU/1/97/046/015 - 56 x 1 tablets EU/1/97/046/009 - 98 tablets 
EU/1/97/046/012 - 14 tableta EU/1/97/046/007 - 28 tableta EU/1/97/046/008 - 56 tableta EU/1/97/046/015 - 56 x 1 tableta EU/1/97/046/009 - 98 tableta
EU/1/97/046/010 - 14 tablets EU/1/97/046/001 - 28 tablets EU/1/97/046/002 - 56 tablets EU/1/97/046/013 - 56 x 1 tablets EU/1/97/046/003 - 98 tablets 
EU/1/97/046/010 - 14 tableta EU/1/97/046/001 - 28 tableta EU/1/97/046/002 - 56 tableta EU/1/97/046/013 - 56 x 1 tableta EU/1/97/046/003 - 98 tableta
What Aprovel looks like and contents of the pack Aprovel 150 mg tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2772 engraved on the other side. 
Aprovel 150 mg tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2772 na drugoj strani.
EU/1/97/046/026 - 14 tablets EU/1/97/046/027 - 28 tablets EU/1/97/046/036 - 30 tablets EU/1/97/046/028 - 56 tablets EU/1/97/046/029 - 56 x 1 tablets EU/1/97/046/033 - 84 tablets EU/1/97/046/039 - 90 tablets EU/1/97/046/030 - 98 tablets 
EU/1/97/046/026 - 14 tableta EU/1/97/046/027 - 28 tableta EU/1/97/046/036 - 30 tableta EU/1/97/046/028 - 56 tableta EU/1/97/046/029 - 56 x 1 tableta EU/1/97/046/033 - 84 tableta EU/1/97/046/039 - 90 tableta EU/1/97/046/030 - 98 tableta
leukocytoclastic vasculitis Musculoskeletal and connective tissue disorders Common: 
Poremećaji mišićno-koštanog sustava i vezivnog tkiva Često:
White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2772 engraved on the other side. 
Bijela do gotovo bijela, bikonveksna, ovalna tableta, s utisnutom oznakom srca na jednoj i brojem 2772 na drugoj strani.
White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2873 engraved on the other side. 
Bijela do gotovo bijela, bikonveksna, ovalna filmom obložena tableta, s utisnutom oznakom srca na jednoj i brojem 2873 na drugoj strani.
If you take certain painkillers, called non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced. 
Diuretici i drugi antihipertenzivni lijekovi: drugi antihipertenzivi mogu pojačati hipotenzivni učinak irbesartana.
White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2871 engraved on the other side. 
Bijela do gotovo bijela, bikonveksna, ovalna filmom obložena tableta, s utisnutom oznakom srca na jednoj i brojem 2871 na drugoj strani.
 If you get any side effects, talk to your doctor or pharmacist. 
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika.
NAME OF THE MEDICINAL PRODUCT Aprovel 75 mg tablets. 
Aprovel 75 mg tablete
NAME OF THE MEDICINAL PRODUCT Aprovel 150 mg tablets. 
Aprovel 150 mg tablete
White to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2872 engraved on the other side. 
Bijela do gotovo bijela, bikonveksna, ovalna filmom obložena tableta, s oznakom srca na jednoj i brojem 2872 na drugoj strani.
NAME OF THE MEDICINAL PRODUCT Aprovel 150 mg film-coated tablets. 
Aprovel 150 mg filmom obložene tablete
Gastrointestinal disorders Common: 
Poremećaji probavnog sustava Često:
orthostatic hypotension* Uncommon: flushing Respiratory, thoracic and mediastinal disorders Uncommon: cough 
Manje često: crvenilo praćeno osjećajem vrućine Poremećaji dišnog sustava, prsišta i sredoprsja Manje često: kašalj
Hepatic impairment 
Oštećena funkcija bubrega
Nederland sanofi-aventis Netherlands B.V. Tel: +31 (0)182 557 755 
Slovenija sanofi-aventis d.o.o. Tel: +386 1 560 48 00
(included in section 1 text) 
(Uključeno u tekst u dijelu 1)
This process is called remodelling. 
Taj proces naziva se preoblikovanje.
This will help to prevent dehydration. 
To će pomoći u sprječavanju dehidracije.
Some side effects could be serious 
Neke nuspojave mogu biti ozbiljne
You should therefore be careful when driving, using machines or performing other tasks that need full attention. 
Stoga morate biti oprezni dok upravljate vozilima, radite sa strojevima ili obavljate druge zadatke koji zahtijevaju Vašu punu pozornost.
The infusion must be conducted according to standard medical practice. 
Infuzija se mora provoditi u skladu sa standardnom liječničkom praksom.
The response rate in these patients was about 52%. 
Stopa odgovora u tih bolesnika bila je približno 52%.
Check with your doctor or nurse if you are not sure. 
Provjerite s liječnikom ili medicinskom sestrom ako niste sigurni.
Local reactions 
Lokalne reakcije
Withdraw an appropriate volume of the concentrate needed, as follows: 
Izvucite odgovarajući volumen potrebnog koncentrata na sljedeći način:
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 
DATUM PRVOG ODOBRENJA / DATUM OBNOVE ODOBRENJA
Median time to normocalcaemia was 4 days. 
Medijan vremena do normokalcemije bio je 4 dana.
Date of first authorisation: 19 November 2012 Date of latest renewal: 24 August 2017 
Datum prvog odobrenja: 19. studeni 2012 Datum posljednje obnove odobrenja: 24. kolovoza 2017
(to appear in roundel) 
(pojavljuje se u krugu)
Unopened bag: 2 years 
Neotvorena vrećica: 2 godine
Time on study (weeks) 
Vrijeme u ispitivanju (tjedni)
2 QUALITATIVE AND QUANTITATIVE COMPOSITION 
KVALITATIVNI I KVANTITATIVNI SASTAV
Frequency cannot be estimated from available data. 
Učestalost se ne može procijeniti iz dostupnih podataka.
The clinical relevance of these findings is unknown. 
Klinički značaj tih nalaza je nepoznat.
Each pack contains one bag. 
Svako pakiranje sadrži jednu vrećicu.
Patients who have received doses higher than those recommended should be carefully monitored. 
Bolesnike koji su primili više doze od preporučenih treba pažljivo pratiti.
No dose adjustment is necessary since bioavailability, distribution and elimination were similar in elderly patients and younger subjects. 
Nije potrebna prilagodba doze s obzirom da je biološka dostupnost, distribucija i eliminacija slična u starijih bolesnika i mlađih ispitanika.
After opening: 24 hours at 2 
Nakon otvaranja: 24 sata na 2
After opening: 24 hours at 2°C - 8°C 
Nakon otvaranja: 24 sata na 2°C-8°C.
The following information is intended for medical or health care professionals only. 
Sljedeće informacije namijenjene su samo liječnicima i zdravstvenim radnicima.
Adults and elderly 
Odrasli i starije osobe
It is normal that old bone is removed and is replaced with new bone material. 
Normalno je da se stara kost razgrađuje i da se nadomješta novim koštanim materijalom.
No symptomatic cases of hypocalcaemia were observed. 
Nisu opaženi simptomatski slučajevi hipokalcemije.
It is important to try and prevent ONJ developing as it a painful condition that can be difficult to treat. 
Važno je pokušati spriječiti razvoj ONČ, jer je to bolno stanje koje može biti problem liječiti.
Special populations (see section 4.2) 
Posebne populacije (vidjeti dio 4.2)
Your doctor will inform you regarding the symptoms associated with hypocalcaemia. 
Liječnik će Vas obavijestiti o simptomima koji su povezani s hipokalcemijom.
It is important that you follow this advice carefully so that the level of calcium in your blood does not become too low in the period after the infusion. 
Važno je da se pažljivo pridržavate tog savjeta kako razina kalcija u krvi ne bi postala preniska u razdoblju nakon infuzije.
Limited data on re-treatment of Paget's disease are available (see section 5.1). 
Dostupni su ograničeni podaci o ponovnom liječenju Pagetove bolesti (vidjeti dio 5.1).
NR Not Reached 
ND nije dosegnuto
If the disease is not treated, bones may become deformed and painful, and may break. 
Ako se bolest ne liječi, kosti mogu postati deformirane i bolne te se mogu slomiti.
Physicians should consider clinical monitoring for these patients. 
Liječnik treba razmotriti kliničko praćenje tih bolesnika.
* Common in Paget's disease only. 
* Često samo u Pagetovoj bolesti.
In order to reduce the risk of developing osteonecrosis of the jaw, there are some precautions you should take. 
Kako bi se smanjio rizik od razvoja osteonekroze čeljusti, postoje neke mjere opreza koje treba poduzeti.
Mutagenicity and carcinogenic potential 
Mutagenost i kancerogeni potencijal
This is especially important in patients who take diuretics (“water pills”) and in elderly patients. 
Ovo je posebno važno za bolesnike koji uzimaju diuretike („tablete za mokrenje“) i za starije bolesnike.
The time to onset of symptoms varied from one day to several months after starting treatment. 
Vrijeme do nastupa simptoma kretalo se u rasponu od jednog dana do nekoliko mjeseci nakon početka liječenja.
** Based on post-marketing reports. 
**Temeljeno na izvješćima poslije stavljanja lijeka u promet.
In some instances the hypocalcaemia may be life-threatening. 
U nekim slučajevima hipokalcemija može biti po život opasna.
The infusion will take at least 15 minutes. 
Infuzija će trajati najmanje 15 minuta.
No interaction studies with other medicinal products have been performed. 
Nisu provedena ispitivanja interakcija s drugim lijekovima.
Zoledronic Acid Hospira may work for longer than one year, and your doctor will let you know if you need to be treated again. 
Zoledronatna kiselina Hospira može djelovati dulje od godine dana, a liječnik će Vam reći ako se trebate ponovno liječiti.
Day 7 
7. dan
You must not be given Zoledronic Acid Hospira if you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby. 
Zoledronatnu kiselinu Hospira ne smijete primijeniti ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete.
Teratology studies were performed in two species, both via subcutaneous administration. 
Teratološka ispitivanja provedena su na dvije vrste, i to u obje supkutanom primjenom.
• Monitoring of serum creatinine should be considered in at-risk patients. 
• treba razmotriti praćenje serumskog kreatinina u rizičnih bolesnika
Ask your doctor, pharmacist or nurse for advice before taking this medicine. 
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri za savjet prije nego uzmete ovaj lijek.
These results were consistent with biochemical marker evidence of normalisation of bone turnover. 
Ti su rezultati bili u skladu s dokazom biokemijskih markera za normalizacije koštane pregradnje.
Attention should also be paid to the possibility of hypomagnesaemia developing during treatment. 
Potrebno je obratiti pozornost i na mogućnost razvoja hipomagnezijemije tijekom liječenja.
Side effects related to the first infusion are very common (occurring in more than 30% of patients) but are less common following subsequent infusions. 
Nuspojave povezane s prvom infuzijom su vrlo česte (javljaju se u više od 30% bolesnika), ali su znatno rjeđe nakon narednih infuzija.
− Urticaria. 
- koprivnjača.
− Your doctor will recommend that you drink enough water before each treatment to help prevent dehydration. 
- Liječnik će Vam savjetovati da prije svakog liječenja popijete dovoljnu količinu vode kako bi se spriječila dehidracija.
This is especially important for the elderly and for patients receiving diuretic therapy. 
To je osobito važno u starijih osoba i bolesnika koji primaju diuretsku terapiju.
Most patients had relief of symptoms after stopping treatment. 
U većine bolesnika simptomi su se povukli nakon prekida liječenja.
The frequency of hypocalcaemia was much lower following subsequent infusions. 
Učestalost hipokalcemije bila je znatno niža nakon narednih infuzija.
If you feel dizzy while taking Zoledronic Acid Hospira, do not drive or use machines until you feel better. 
Ako osjećate omaglicu dok uzimate Zoledronatnu kiselinu Hospira, nemojte upravljati vozilima ili raditi sa strojevima dok se ne budete osjećali bolje.
• A single dose of zoledronic acid should not exceed 5 mg and the duration of infusion should be at least 15 minutes (see section 4.2). 
• jedna doza zoledronatne kiseline ne smije prijeći 5 mg, a trajanje infuzije treba biti najmanje 15 minuta (vidjeti dio 4.2).
Manufacturer Hospira UK Limited Horizon 
Proizvođač Hospira UK Limited Horizon
Age, body weight, gender and creatinine clearance appear to have no effect on zoledronic acid systemic exposure. 
Čini se da dob, tjelesna težina, spol i klirens kreatinina ne utječu na sistemsku izloženost zoledronatnoj kiselini.
As with other bisphosphonates, the retention time of zoledronic acid in bones is very long. 
Kao i s drugim bisfosfonatima, vrijeme zadržavanja zoledronatne kiseline u kostima je vrlo dugo.
Clinical experience with acute overdose is limited. 
Kliničko iskustvo s akutnim predoziranjem je ograničeno.
− Severe allergic reaction: shortness of breath, swelling mainly of the face and throat. 
- teška alergijska reakcija: nedostatak zraka, oticanje koje uglavnom zahvaća lice i grlo.
Your doctor can recommend a mild pain reliever such as ibuprofen or paracetamol to reduce these side effects. 
Vaš liječnik će Vam preporučiti blagi lijek protiv bolova poput ibuprofena ili paracetamola, kako bi se smanjile ove nuspojave.
Patients receiving zoledronic acid 4 mg reported less increase in pain than those receiving placebo, and the difference reached significance at months 3, 9, 21 and 24. 
Bolesnici koji su primali zoledronatnu kiselinu u dozi od 4 mg prijavili su manje povećanje boli od onih koji su primali placebo, a ta je razlika bila značajna u 3., 9., 21. i 24. mjesecu.
Patients should be informed about symptoms of hypocalcaemia and receive adequate clinical monitoring during the period of risk. 
Bolesnike treba informirati o simptomima hipokalcemije i klinički nadzirati tijekom perioda rizika.
Pharmacotherapeutic group: Medicinal products for treatment of bone diseases, bisphosphonates, ATC code: M05BA08 
Farmakoterapijska skupina: lijekovi za liječenje bolesti kostiju, bisfosfonati, ATK oznaka: M05BA08
Cases of severe hypocalcaemia requiring hospitalisation have been reported. 
Prijavljeni su slučajevi teške hipokalcemije koji zahtijevaju hospitalizaciju.
Concentrate for solution for infusion (sterile concentrate) 
Koncentrat za otopinu za infuziju (sterilni koncentrat)
The early disposition phases (α and β, with t½ values above) presumably represent rapid uptake into bone and excretion via the kidneys. 
Rane faze dispozicije (α i β, s t½ vrijednostima navedenim gore) vjerojatno predstavljaju brzu apsorpciju u kost i izlučivanje putem bubrega.
Tell your doctor about any of the following serious side effects straight away: 
Odmah obavijestite svog liječnika o svakoj od sljedećih ozbiljnih nuspojava:
In Paget's disease, bone remodelling is too rapid and new bone is formed in a disordered fashion, which makes it weaker than normal. 
Kod Pagetove bolesti preoblikovanje kosti je prebrzo te se nova kost stvara na poremećen način, čime postaje slabija nego normalno.
The symptoms are usually mild to moderate and go away within three days. 
Simptomi su obično blagi do umjereni i nestaju unutar tri dana.
ONJ can also occur after stopping treatment. 
ONČ se također može javiti nakon prestanka liječenja.
Pamidronate 90 mg (N=99) *p-values compared to pamidronate. 
pamidronat 90 mg (n=99) *p-vrijednosti naspram pamidronata
This uptake into bone is common for all bisphosphonates and is presumably a consequence of the structural analogy to pyrophosphate. 
Ova pohrana u kost je zajednička za sve bisfosfonate i vjerojatno je posljedica analogne strukture s pirofosfatom.
It belongs to a group of medicines called bisphosphonates and is used to treat Paget's disease of the bone in adults. 
Pripada skupini lijekova koji se nazivaju bisfosfonati i koji se koriste za liječenje Pagetove bolesti kostiju u odraslih.
• Transient increase in serum creatinine may be greater in patients with underlying impaired renal function. 
• prolazno povećanje serumskog kreatinina može biti veće u bolesnika s podležećim oštećenjem bubrega
** Accounts for all skeletal events, the total number as well as time to each event during the trial 
** Odnosi se na sve koštane događaje, njihov ukupni broj i vrijeme do svakog pojedinog događaja tijekom ispitivanja.
Painful redness and/or swelling of the eye. 
- bolno crvenilo i/ili oticanje oka.
Other disturbances of mineral metabolism must also be effectively treated (e.g. diminished parathyroid reserve, intestinal calcium malabsorption). 
Druge poremećaje metabolizma minerala također treba učinkovito liječiti (npr. smanjiti paratiroidne rezerve, crijevnu malapsorpciju kalcija).
The percentage of patients who experienced adverse reactions was lower in a smaller study (19.5%, 10.4%, 10.7% after the first, second and third infusion, respectively), where prophylaxis against adverse reactions was used. 
Postotak bolesnika koji su imali nuspojave bio je niži u manjoj studiji (19,5%, 10,4%, 10,7% nakon prve, druge, odnosno treće infuzije) kad je bila korištena profilaksa protiv nuspojava.
If you wear dentures you should make sure these fit properly. 
Ako nosite protezu, pazite da dobro prilježe.
Stable for 24 hours at 2 
Rok valjanosti: Stabilan 24 sata na 2
CLcr is calculated from serum creatinine using the Cockcroft-Gault formula. 
CLcr izračunava se pomoću Cockcroft-Gaultove formule.
The selective action of bisphosphonates on bone is based on their high affinity for mineralised bone, but the precise molecular mechanism leading to the inhibition of osteoclastic activity is still unclear. 
Selektivno djelovanje bisfosfonata na kost temelji se na njihovom visokom afinitetu za mineraliziranu kost, no točan molekularni mehanizam koji dovodi do inhibicije osteoklastične aktivnosti još nije jasan.
For information on the infusion of Zoledronic Acid Hospira, see section 6.6. 
Za informacije o infuziji Zoledronatne kiseline Hospira, vidjeti dio 6.6.
The mean time of ending the Extended Observation Period due to the need for Paget's re-treatment from the initial dose was longer for zoledronic acid (7.7 years) than for risedronate (5.1 years). 
Srednje vrijeme od završetka produljenog perioda praćenja od početne doze, zbog potrebe za ponovnim liječenjem Pagetove bolesti, bilo je dulje za zoledronatnu kiselinu (7,7 godina) nego za risedronat (5,1 godina).
The efficacy of one infusion of 5 mg zoledronic acid versus daily doses of 30 mg risedronate for 2 months was demonstrated in two 6-month comparative trials. 
Djelotvornost jedne infuzije 5 mg zoledronatne kiseline naspram dnevnih doza od 30 mg risedronata za 2 mjeseca bila je pokazana u dva 6-mjesečna usporedna ispitivanja.
If a lower dose of Zoledronic Acid Hospira is required, first withdraw the appropriate volume as indicated below and then dilute it further with 100 ml of infusion solution. 
Ako je potrebna niža doza Zoledronatne kiseline Hospira, prvo izvucite odgovarajući volumen kako je navedeno niže i potom ga dodatno razrijedite sa 100 ml otopine za infuziju.
p-value Skeletal morbidity rate p-value Risk reduction of suffering from multiple events** (%) 
p-vrijednost stopa koštanog pobola p-vrijednost smanjenje rizika od višestrukih događaja** (%)
Additional information on handling of Zoledronic Acid Hospira, including guidance on preparation of reduced doses, is provided in section 4.2. 
Dodatne informacije o rukovanju Zoledronatnom kiselinom Hospira, uključujući upute za pripremu sniženih doza, nalaze se u dijelu 4.2.
Over the first 24 hours, 39 ± 16% of the administered dose is recovered in the urine, while the remainder is principally bound to bone tissue. 
Tijekom prvih 24 sata, 39 ± 16% primijenjene doze izlučuje se mokraćom, dok se ostatak uglavnom veže na koštano tkivo.
After 6 months, zoledronic acid showed 96% (169/176) and 89% (156/176) response and serum alkaline phosphatase (SAP) normalisation rates compared to 74% (127/171) and 58% (99/171) for risedronate (all p<0.001). 
Nakon 6 mjeseci, zoledronatna kiselina je pokazala 96% (169/176) i 89% (156/176) odgovor i normalizaciju razina alkalne fosfataze u serumu naspram 74% (127/171) i 58% (99/171) za risedronat (sve p<0,001).
The usual dose is 5 mg, given to you as one single infusion into a vein by your doctor or nurse. 
Uobičajena doza je 5 mg, a daje Vam je liječnik ili medicinska sestra u obliku jednokratne infuzije u venu.
It is especially important for your doctor to know all the medicines you are taking, especially if you are taking any medicines known to be harmful to your kidneys (e.g. aminoglycosides) or diuretics (“waterpills”) that may cause dehydration. 
Osobito je važno da Vaš liječnik zna za sve lijekove koje uzimate, naročito ako uzimate lijekove za koje je poznato da štetno djeluju na Vaše bubrege (npr. aminoglikozidi) ili ako uzimate diuretike ("tablete za mokrenje") koji mogu uzrokovati dehidraciju.
• Patients, especially elderly patients and those receiving diuretic therapy, should be appropriately hydrated prior to administration of zoledronic acid. 
• bolesnici, pogotovo stariji i oni koji primaju diuretsku terapiju, trebaju biti prikladno hidrirani prije primjene zoledronatne kiseline
Low levels of phosphate in the blood. 
Niske razine fosfata u krvi.
In the Paget's disease trials, symptomatic hypocalcaemia was observed in approximately 1% of patients, in all of whom it resolved. 
U kliničkim ispitivanjima Pagetove bolesti opažena je simptomatska hipokalcemija u otprilike 1% bolesnika, od koje su se svi oporavili.
Confusion 
konfuzija